Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance

被引：11

作者：

Yang-Kolodji, Gloria ^{[1
]}

Mumenthaler, Shannon M. ^{[2
]}

Mehta, Arjun ^{[1
]}

Ji, Lingyun ^{[3
]}

Tripathy, Debu ^{[1
,4
]}

机构：

[1] Univ So Calif, Dept Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA

[2] Univ So Calif, Ctr Appl Mol Med, Los Angeles, CA 90033 USA

[3] Univ So Calif, Dept Prevent Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA

[4] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX USA

来源：

BIOMARKERS | 2015年 / 20卷 / 05期

关键词：

Biomarker; breast cancer; cell model; drug response; trastuzumab resistance; METASTATIC BREAST-CANCER; OVERCOMING RESISTANCE; PARADIGM-SHIFT; SINGLE-AGENT; TRASTUZUMAB; LAPATINIB; SURVIVAL; EFFICACY; SAFETY; KI67;

D O I：

10.3109/1354750X.2015.1068865

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Objective: To identify clinically relevant predictive biomarkers of trastuzumab resistance. Material and methods: MTT, FACS assays, immunoblotting and immunocytochemistry were used to phenotypically characterize drug responses of two cell models BT474R and SKBR3R. Student's t-test and Spearman's correlation were applied for statistic analysis. Results: The activity of a downstream effector of the HER2 pathway phosphorylated ribosomal protein S6 (p-rpS6), was suppressed by trastuzumab in the parental cell lines yet remained unchanged in the resistant cells following treatment. The level of p-rpS6 was inversely correlated to the drug induced growth inhibition of trastuzumab-resistant cells when they are treated with selected HER2 targeting drugs. Conclusion: p-rpS6 is a robust post-treatment indicator of HER2 pathway-targeted therapy resistance.

引用

页码：313 / 322

页数：10

共 47 条

[11] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[12] CALCULATING SYNERGISTIC AND ANTAGONISTIC RESPONSES OF HERBICIDE COMBINATIONS [J].

COLBY, SR .

WEEDS, 1967, 15 (01) :20-&

[13] Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group [J].

Dowsett, Mitch ;

Nielsen, Torsten O. ;

A'Hern, Roger ;

Bartlett, John ;

Coombes, R. Charles ;

Cuzick, Jack ;

Ellis, Matthew ;

Henry, N. Lynn ;

Hugh, Judith C. ;

Lively, Tracy ;

McShane, Lisa ;

Paik, Soon ;

Penault-Llorca, Frederique ;

Prudkin, Ljudmila ;

Regan, Meredith ;

Salter, Janine ;

Sotiriou, Christos ;

Smith, Ian E. ;

Viale, Giuseppe ;

Zujewski, Jo Anne ;

Hayes, Daniel F. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22) :1656-1664

[14] Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics [J].

Ellis, Matthew J. ;

Tao, Yu ;

Luo, Jingqin ;

A'Hern, Roger ;

Evans, Dean B. ;

Bhatnagar, Ajay S. ;

Ross, Hilary A. Chaudri ;

von Kameke, Alexander ;

Miller, William R. ;

Smith, Ian ;

Eiermann, Wolfgang ;

Dowsett, Mitch .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (19) :1380-1388

[15] Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial [J].

Gianni, Luca ;

Dafni, Urania ;

Gelber, Richard D. ;

Azambuja, Evandro ;

Muehlbauer, Susanne ;

Goldhirsch, Aron ;

Untch, Michael ;

Smith, Ian ;

Baselga, Jose ;

Jackisch, Christian ;

Cameron, David ;

Mano, Max ;

Pedrini, Jose Luiz ;

Veronesi, Andrea ;

Mendiola, Cesar ;

Pluzanska, Anna ;

Semiglazov, Vladimir ;

Vrdoljak, Eduard ;

Eckart, Michael J. ;

Shen, Zhenzhou ;

Skiadopoulos, George ;

Procter, Marion ;

Pritchard, Kathleen I. ;

Piccart-Gebhart, Martine J. ;

Bell, Richard .

LANCET ONCOLOGY, 2011, 12 (03) :236-244

[16] Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer [J].

Gonzalez-Angulo, A. M. ;

Blumenschein, G. R., Jr. .

CANCER TREATMENT REVIEWS, 2013, 39 (04) :313-320

[17] High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller [J].

Gonzalez-Angulo, Ana M. ;

Litton, Jennifer K. ;

Broglio, Kristine R. ;

Meric-Bernstam, Funda ;

Rakkhit, Ronjay ;

Cardoso, Fatima ;

Peintinger, Florentia ;

Hanrahan, Emer O. ;

Sahin, Aysegul ;

Guray, Merih ;

Larsimont, Denis ;

Feoli, Francesco ;

Stranzl, Heidi ;

Buchholz, Thomas A. ;

Valero, Vicente ;

Theriault, Richard ;

Piccart-Gebhart, Martine ;

Ravdin, Peter M. ;

Berry, Donald A. ;

Hortobagyi, Gabriel N. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5700-5706

[18] Targeting the translational machinery as a novel treatment strategy for hematologic malignancies [J].

Hagner, Patrick R. ;

Schneider, Abraham ;

Gartenhaus, Ronald B. .

BLOOD, 2010, 115 (11) :2127-2135

[19]

Hayashi M, 2012, FRONT ONCOL, V2, P62

[20] The role of S6K1 in ER-positive breast cancer [J].

Holz, Marina K. .

CELL CYCLE, 2012, 11 (17) :3159-3165

← 1 2 3 4 5 →